Navigation Links
EUREKA invested over 300 million euros in industrial initiatives over the past year
Date:6/29/2011

Chairmanship had put as the top priority this year. The high focus on clean-tech was reflective of the commitment of EUREKA's member countries to deal with the large, critical challenges facing mankind today, including energy and the environment, climate change and security. In the spirit of promoting further innovation in clean technology, during the event EUREKA marked the launch of its new EUREKA Clean-Tech Action, a campaign focused on generating cooperative industrial R&D projects in the clean-tech sector. EUREKA currently has over 100 active clean-tech projects, at a cost of over 200 million Euros.

During the third meeting of the Chairmanship, held in April this year in Haifa and Nazareth, it was determined that EUREKA representatives will formally announce to the European Commission that the EUREKA Network will become the preferred aid program by European industry, for cooperation industrial R&D. The event also presented an opportunity to highlight cooperation between Jewish and Arab entrepreneurs from the Galilee, and served to greater encourage cooperation with minorities throughout Europe.

The events this week also follow the recently held 17th Inter-Parliamentary Conference, which took place in late May at the Israeli Knesset. With the participation of several ministers, leading Israeli and European policy-makers, industry representatives, funding bodies, and academics, the conference sessions explored how governments can more effectively support industrial innovation as a means for business generation in times of economic crisis. There was also a special welcome in the Knesset hall to European Parliamentarians from Mr. Meir Sheetrit, Chairman of the Knesset Committee on Science and Technology.

In early June, at an investors conference held in Jerusalem, EUREKA announced the launch of "E!nnoVest", a new search and match web tool for investors and companies, and the first pan-European EUREKA investment platform. Thi
'/>"/>

Contact: Piotr Pogorzelski
piotr.pogorzelski@eurekanetwork.org
322-777-0979
EUREKA
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Lithuanian scientists clean up at 2011 EUREKA Innovation Award
2. EUREKA IPC Resolution commits growth in market-oriented R&D projects
3. EUREKA, the largest European network for industrial R&D and innovation, launches E!NNOVEST
4. Eureka! Air cargo scanning wins top prize
5. US invested $139 billion in health research in 2009
6. Research shows that time invested in practicing pays off for young musicians
7. MarketsandMarkets: Global Touchless Sensing Market to be Worth $3656.8 Million and Global Gesture Recognition Market Worth $625 Million by 2015
8. MU signs $5 million agreement with Coulter Translational Research Partnership Program
9. MSU nets $5 million grant to increase dairy production efficiency
10. Rensselaer researchers secure $2.7 million NIH grant to advance scarless surgery
11. NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Parts of the primordial soup in which life arose have ... the University of East Anglia. , Research published today in ... in plants, yeast and very likely also in animals still ... origin of life some four billion years ago. , ... pond or ocean as a result of the combination of ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... group of European experts on biodiversity will gather from the ... to further improve the transfer of biodiversity knowledge from the ... will take part in a project funded by the European ... by researchers and practitioners to help all actors in the ...
... in milk powder and in meat-based baby food, residues ... the University of Almera (Spain) have developed a system ... such as tilmicosine, or antiparasitic drugs, such as levamisole, ... but they can remain later in food. Scientists from ...
... genetic testing that can indicate their range of risk ... appreciably drive up or diminish test recipients, demand for ... performed by researchers at the National Institutes of Health ... the May 17, 2012 early online issue of ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2A new method detects traces of veterinary drugs in baby food 2NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... and rejected the previously announced unsolicited proposal from Astellas ... of $16.00 per share. After careful consideration of ... the CV Therapeutics board concluded that the Astellas proposal ...
... February 20 Nyenrode Business,Universiteit has awarded a ... the field of microeconomics, competitive strategy and cluster,theory. ... of the modern,field of strategy and the world,s ... and competitive strategy. Professor Porter will receive,the Honorary ...
... Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 ... ) today announced its financial results for the three and twelve ... of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for ... Adjusted diluted EPS of $0.26 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: